News | June 08, 2015

Center for Biomedical Research Partners With Florida Proton Center in Clinical Registry

Initiative will monitor clinical outcomes and long-term follow-up of cancer patients receiving proton therapy

Center for Biomedical Research, Ackerman Cancer Center, proton therapy, registry

June 8, 2015 - The Center for Biomedical Research (CBR) is partnering with the Ackerman Cancer Center as part of a clinical meta-registry for clinical outcomes and long-term follow-up of cancer patients receiving proton therapy.

Ackerman has joined the registry study developed and managed by the CBR in collaboration with the Provision Center for Proton Therapy. The registry study meets all guidelines as outlined in the Agency for Healthcare Research and Quality's (AHRQ) guidelines for Registries for Evaluating Patient Outcomes.

"With the PRO 0425 study, we are collecting data that will allow us to compare information across disease sites and treatment modalities and provide a unique window into the long-term effectiveness of proton therapy," said Marcio Fagundes, M.D., medical director for Provision Center for Proton Therapy and principal investigator.

Located in Jacksonville, Fla., Ackerman is the first private, physician-owned practice to offer proton therapy. The center began treating patients in late April.

The Center for Biomedical Research (CBR) specializes in the management of clinical trials and has a lengthy history of managing groundbreaking clinical trials such as Herceptin, Avastin and most recently Imbruvica, of which CBR was the only clinical research site in the Southeastern United States. The Center for Biomedical Research has managed hundreds of clinical trials with a particular focus on medical oncology, proton therapy and positron emission tomography (PET) imaging. CBR is regionally noted for its expertise in conducting pharmaceutical trials targeting smaller, rare cancers with specific tumor mutations.

For more information: www.biomed-research.com

Related Content

Clinical Trial Testing Topical Gel to Reduce Breast Density
News | Breast Density | June 19, 2018
Women with dense breast tissue soon might be adding a new product to their skincare routine to help them fight breast...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Report Finds Identifying Patients for Lung Cancer Screening Not So Simple
News | Lung Cancer | June 18, 2018
New findings in the current issue of The American Journal of Managed Care suggest that getting the right patients to...
Elekta Unity High-Field MR-Linac Receives CE Mark
News | Image Guided Radiation Therapy (IGRT) | June 18, 2018
Elekta announced that its Elekta Unity magnetic resonance radiation therapy (MR/RT) system has received CE mark,...
Washington University in St. Louis Begins Clinical Treatments With ViewRay MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | June 14, 2018
June 14, 2018 — The Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in S
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Accuray TomoTherapy System Beneficial in Two Total Body Irradiation Studies
News | Radiation Therapy | June 13, 2018
Recently published data from two new studies demonstrate the benefits of Accuray’s TomoTherapy System in the delivery...
Women More Likely to Use Other Preventive Health Services Following Mammography
News | Mammography | June 13, 2018
Medicare beneficiaries who undergo breast cancer screening with mammography are more likely than unscreened women to...
Reduced hippocampal volume on MRI

This figure shows reduced hippocampal volume over the course of 6 years as seen on progressive volumetric analysis and also coronal MRI evaluations (arrows).Progressive volume loss in the mesial temporal lobe on MRI is a characteristic imaging feature of AD. This patient was a case of Alzheimer’s Dementia.

 

News | Neuro Imaging | June 12, 2018
According to a UCLA Medical Center study, a new technology shows the potential to help doctors better determine when...
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
Overlay Init